• Issue
    2021
    i-v, 861-1187

ISSUE INFORMATION
Free Access

Issue information

  • Pages: i-v
  • First Published: 07 July 2021

REVIEW ARTICLE
Free Access

Clinical and economic impacts of explicit tools detecting prescribing errors: A systematic review

  • Pages: 877-886
  • First Published: 25 March 2021
Clinical and economic impacts of explicit tools detecting prescribing errors: A systematic review

Very little is known regarding the clinical and economic impact of the prospective use of explicit tools detecting prescribing errors. We found a significant impact of STOPP/START on adverse drug reactions and medication costs and a significant impact of FORTA on falls, activities of daily living and adverse drug reactions. These findings suggest that explicit tools support reducing the complexity of therapeutic management and tools-based interventions could have a usefulness in clinical practice.

REVIEW ARTICLE
Free Access

Albumin for cirrhosis-related complications

  • Pages: 887-894
  • First Published: 07 June 2021
Albumin for cirrhosis-related complications

There is little evidence supporting the routine administration of albumin in hospitalized patients with cirrhosis except in cases of spontaneous bacterial peritonitis, and in selected patients who have hepatorenal syndrome or are undergoing large volume paracentesis. Recent evidence suggests possible benefits of longer-term albumin administration in subgroups of non-hospitalized patients with decompensated cirrhosis, but more research is needed.

REVIEW ARTICLE
Free Access

Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta-analysis

  • Pages: 895-906
  • First Published: 25 March 2021
Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta-analysis

IL-17 inhibitors lead to a higher response rates in patients with AS or PsA. IL-17 inhibitors might be more effective for patients with AS or PsA who previously not used TNF inhibitors. IL-17 inhibitors might be well tolerated for patients with PsA, but increased treatment-emergent adverse events and infection in AS patients.

PHARMACOGENETICS

Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients

  • Pages: 942-949
  • First Published: 25 March 2021
Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients

This study reveals that the IL28B genotype at the baseline is a good predictor of SVR and relapse rates after applying the therapy with SOF and DCV in Egyptian patients suffering from HCV-4. This supports the incorporation of the IL28B genotype testing in the treatment algorithm of HCV-4 patients to identify patients that can be successfully treated with SOF and DCV.

ORIGINAL ARTICLE

Risk comparison of beta-lactam-induced anaphylaxis: Therapeutic stratification analysis in a Vietnamese pharmacovigilance database

  • Pages: 950-956
  • First Published: 10 February 2021
Risk comparison of beta-lactam-induced anaphylaxis: Therapeutic stratification analysis in a Vietnamese pharmacovigilance database

This study suggests a new approach that identifies the different risks of reporting anaphylaxis in beta-lactam users, rather than traditional case/non-case method.

ORIGINAL ARTICLE

A qualitative study on the development of pharmacist-managed clinics in Taiwan

  • Pages: 966-974
  • First Published: 10 February 2021
A qualitative study on the development of pharmacist-managed clinics in Taiwan

This study used semi-structured interviews to understand implementation issues and perceptions of pharmacist-managed clinics in Taiwan. Participants described influential factors in establishing PMCs, including clinical expertise, attitude towards patient care and trust building with collaborating physicians. Operational concerns included role clarifications, manpower shortage, inadequate advanced training or certification, regulatory issues and a lack of service promotion.

ORIGINAL ARTICLE

Estimation of sodium-glucose cotransporter 2 inhibitor–related genital and urinary tract infections via electronic medical record–based common data model

  • Pages: 975-983
  • First Published: 10 February 2021
Estimation of sodium-glucose cotransporter 2 inhibitor–related genital and urinary tract infections via electronic medical record–based common data model

1. We identified how the physician approached SGLT2i-related GTI or UTI at each step in the real-world setting. 2. For mild side effects, where quantified diagnostic criteria do not exist, it is even more difficult to detect side effects with CDM.

ORIGINAL ARTICLE

Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials

  • Pages: 984-992
  • First Published: 18 February 2021
Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials

Both non-TNF biologics and JAK inhibitors have similar effects in patients with active RA that are refractory to anti-TNF treatment. There were no differences with regard to safety among the treatments.

ORIGINAL ARTICLE

Intravenous acetaminophen (at 15 mg/kg/dose every 6 hours) in critically ill preterm neonates with patent ductus arteriosus: A prospective study

  • Pages: 1010-1019
  • First Published: 27 February 2021
Intravenous acetaminophen (at 15 mg/kg/dose every 6 hours) in critically ill preterm neonates with patent ductus arteriosus: A prospective study

Intravenous acetaminophen at 15 mg/kg/dose every 6 hours was efficacious in four-fifths of the preterm neonates with PDA with a lower incidence of hepatotoxicity, and acute kidney injury.

ORIGINAL ARTICLE

Safety of dexmedetomidine for the control of agitation in critically ill traumatic brain injury patients: a descriptive study

  • Pages: 1020-1026
  • First Published: 19 February 2021
Safety of dexmedetomidine for the control of agitation in critically ill traumatic brain injury patients: a descriptive study

In a retrospective descriptive study, dexmedetomidine appeared safe and efficacious for the management of agitation following traumatic brain injury. Prospective controlled studies are needed to confirm these findings.

ORIGINAL ARTICLE

Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database

  • Pages: 1027-1040
  • First Published: 01 March 2021
Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database

This study highlight the need for careful prescribing of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) particularly in patients with previous gastrointestinal and hematological diseases and in polytherapy focusing on potential drug-drug interactions (DDIs).

ORIGINAL ARTICLE

Impact and barriers of a pharmacist-led practice with computerized reminders on intravenous to oral antibiotic conversion for community-acquired pneumonia inpatients

  • Pages: 1055-1061
  • First Published: 07 June 2021
Impact and barriers of a pharmacist-led practice with computerized reminders on intravenous to oral antibiotic conversion for community-acquired pneumonia inpatients

The proportion of patients who converted to oral therapy on the day patients were eligible for the conversion was significantly increased, and the length of IV antibiotic therapy days and the length of hospital stay for patients were both significantly shorter after the pharmacists’ intervention with computerized reminders on IV-PO antibiotic conversion for community-acquired pneumonia (CAP) inpatients.

ORIGINAL ARTICLE

Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study

  • Pages: 1062-1070
  • First Published: 26 February 2021
Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study

Evolution of cytomegalovirus viral load and serology tests in one pregnant patient, in which viral reactivation was detected. She received a single dose of tocilizumab and methylprednisolone therapy for 15 days. Baseline IgM antibodies and amniotic fluid polymerase-chain-reaction were negative, but they became positive 6 days after tocilizumab infusion and viral load was detected on day 13.

ORIGINAL ARTICLE

Safe handling and delivery of biological medications during the COVID-19 pandemic

  • Pages: 1071-1082
  • First Published: 18 March 2021
Safe handling and delivery of biological medications during the COVID-19 pandemic

Descriptive study of the handlings and delivery of biological medications to patients home during the COVID-19 pandemic. Name and number of medications delivered to patients as well as the cities delivered to were included.

ORIGINAL ARTICLE

Clinical outcomes of pharmaceutical care intervention in HIV positive patients with hypertension: A randomized controlled study

  • Pages: 1083-1094
  • First Published: 05 March 2021
Clinical outcomes of pharmaceutical care intervention in HIV positive patients with hypertension: A randomized controlled study

  • This randomized controlled study evaluated the impacts of a 12-month pharmaceutical care intervention programme on clinical outcomes in HIV positive patients with hypertension.
  • The interventions significantly improved blood pressure control and adherence to medications, but had no statistically significant effect on virologic control.

ORIGINAL ARTICLE

Involvement of emergency medicine pharmacists in stroke thrombolysis: A cohort study

  • Pages: 1095-1102
  • First Published: 22 March 2021
Involvement of emergency medicine pharmacists in stroke thrombolysis: A cohort study

A multit-facted approach to stroke design including formal integration of the EM pharmacist into the acute stroke team was associated with improvements in DTNT and warrants further evaluation.

ORIGINAL ARTICLE

Outcomes of a pharmacist-driven vancomycin monitoring initiative in a community hospital

  • Pages: 1103-1108
  • First Published: 25 March 2021
Outcomes of a pharmacist-driven vancomycin monitoring initiative in a community hospital

Vancomycin administration requires close monitoring of serum vancomycin levels and appropriate dosing based on patients’ renal function, underlying infection type and serum concentration levels. This article explores the implications of a pharmacist-driven vancomycin monitoring initiative, which was implemented at Mercy Catholic Medical Center's Philadelphia Campus (MPC) in July 2016. Pharmacist-driven vancomycin monitoring significantly improved the monitoring compliance of vancomycin trough levels; specifically, the initiative improved the total percentage of patients attaining desired trough goals and helped reduce further renal insult from supratherapeutic vancomycin level.

ORIGINAL ARTICLE

Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients

  • Pages: 1117-1128
  • First Published: 25 March 2021
Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients

The graph showed that WZC+TAC co-administration and CYP3A5 variants are the two major factors that affect the PK of TAC. Dosing guidelines are made according to the results of PPK model analysis, allowing individualized administration of TAC for different KTR patients.

ORIGINAL ARTICLE

The outcomes and acceptance of pressurized metered-dose inhaler bronchodilators with venturi mask modified spacer in the outpatient emergency department during the COVID-19 pandemic

  • Pages: 1129-1138
  • First Published: 25 March 2021
The outcomes and acceptance of pressurized metered-dose inhaler bronchodilators with venturi mask modified spacer in the outpatient emergency department during the COVID-19 pandemic

The use of nebulizer is discouraged during the COVID-19 pandemic. The pMDI bronchodilators delivered via Venturi mask modified spacer appeared to be comparable to nebulizer in treating mild to moderate asthma and COPD exacerbation in the outpatient ED setting. The Venturi mask modified spacer can be a cheap and effective alternative to the commercial spacer in a resource-limited situation.

ORIGINAL ARTICLE

Quality assessment of clinical guidelines on probiotics therapy in children with IBD using the AGREE II instrument

  • Pages: 1155-1165
  • First Published: 25 March 2021
Quality assessment of clinical guidelines on probiotics therapy in children with IBD using the AGREE II instrument

Guidelines that addressed the treatments of pediatric IBD were evaluated with the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument to assess methodological quality. The domain percentage scores are graphically visualized in this figure.

ORIGINAL ARTICLE

Pharmacokinetic comparison of nalbuphine with single injection and patient-controlled analgesia mimic method in healthy Chinese volunteers

  • Pages: 1166-1172
  • First Published: 03 May 2021
Pharmacokinetic comparison of nalbuphine with single injection and patient-controlled analgesia mimic method in healthy Chinese volunteers

Compared with those in the single-injection group, the area under concentration-time curve (AUC0–t) and effective analgesic concentration durations in the patient-controlled analgesia (PCA) group were similar, whereas Cmax was decreased significantly. Therefore, the PCA method was more suitable for the clinical application of nalbuphine injection owing to the superiority of lower concentration fluctuation and the improved safety profile.

CASE REPORT
Open Access

Methotrexate-associated lymphoproliferative disorder with an osteolytic vertebral lesion in an elderly patient with rheumatoid arthritis: A case report

  • Pages: 1178-1181
  • First Published: 25 March 2021
Methotrexate-associated lymphoproliferative disorder with an osteolytic vertebral lesion in an elderly patient with rheumatoid arthritis: A case report

Bone lesions in LPDs mimic those of metastatic cancer. MTX-LPD should be considered in patients on MTX presenting with mass lesions.

CASE REPORT

Ibalizumab-uiyk as a bridge therapy for a patient with drug-resistant HIV-1 infection receiving chemotherapy: A case report

  • Pages: 1185-1187
  • First Published: 10 June 2021
Ibalizumab-uiyk as a bridge therapy for a patient with drug-resistant HIV-1 infection receiving chemotherapy: A case report

Our case describes a patient with drug-resistant HIV infection and diffuse large B-cell lymphoma (DLBCL), who initiated chemotherapy which had drug interactions with his antiretroviral therapy (ART). During chemotherapy, darunavir/cobicistat was held and ibalizumab-uiyk was initiated, as this medication has no known drug-drug interactions, to ensure he was on three active HIV medications. Ibalizumab-uiyk may be used as bridge therapy for patients with drug-resistant HIV infection undergoing chemotherapy.